about
Analysis of binding sites on complement factor I that are required for its activityLigand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approachesMutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndromeGenetic, molecular and functional analyses of complement factor I deficiencyIn silico mechanistic profiling to probe small molecule binding to sulfotransferasesIntegrated structure- and ligand-based in silico approach to predict inhibition of cytochrome P450 2D6.Functional characterization of two novel non-synonymous alterations in CD46 and a Q950H change in factor H found in atypical hemolytic uremic syndrome patients.Zebrafish ProVEGF-C expression, proteolytic processing and inhibitory effect of unprocessed ProVEGF-C during fin regeneration.Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins.Identification of novel small molecule inhibitors of activated protein C.Theileria parasites secrete a prolyl isomerase to maintain host leukocyte transformationIn silico design of low molecular weight protein-protein interaction inhibitors: Overall concept and recent advances.Complement inhibitor C4b-binding protein-friend or foe in the innate immune system?Kaposi's sarcoma-associated herpes virus complement control protein: KCP--complement inhibition and more.Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.Computational investigations of hERG channel blockers: New insights and current predictive models.Computational Biology and Chemistry in MTi: Emphasis on the Prediction of Some ADMET Properties.Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.Characterization of the complement inhibitory function of rhesus rhadinovirus complement control protein (RCP).Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group.A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells.In silico model of the human ClC-Kb chloride channel: pore mapping, biostructural pathology and drug screening.AMMOS2: a web server for protein-ligand-water complexes refinement via molecular mechanicsAnalysis of binding sites on complement factor I using artificial N-linked glycosylationThe Kaposi's sarcoma-associated herpesvirus complement control protein mimics human molecular mechanisms for inhibition of the complement system.An exploration of the 3D chemical space has highlighted a specific shape profile for the compounds intended to inhibit protein-protein interactions.Identification of insulin-sensitizing molecules acting by disrupting the interaction between the Insulin Receptor and Grb14.FAF-Drugs4: free ADME-tox filtering computations for chemical biology and early stages drug discovery.Expression and functional characterization of two natural heparin-binding site variants of antithrombin.Breast cancer targeting through inhibition of the endoplasmic reticulum-based apoptosis regulator Nrh/BCL2L10.Acute genetic ablation of pendrin lowers blood pressure in mice.The Kaposi's sarcoma-associated herpesvirus complement control protein (KCP) binds to heparin and cell surfaces via positively charged amino acids in CCP1-2.Discovery of novel inhibitors of vascular endothelial growth factor-A-Neuropilin-1 interaction by structure-based virtual screening.Insights into molecular mechanisms of drug metabolism dysfunction of human CYP2C9*30.Structural requirements of anticoagulant protein S for its binding to the complement regulator C4b-binding proteinCharacterization of the complement inhibitory function of Rhesus rhadinovirusPan-assay interference compounds (PAINS) that may not be too painful for chemical biology projectsAnti-Factor B Antibodies and Acute Postinfectious GN in ChildrenGly197Arg mutation in protein C causes recurrent thrombosis in a heterozygous carrierAnalysis of protein missense alterations by combining sequence- and structure-based methods
P50
Q24645042-59D1A352-C247-4864-8FA2-22E728ECF479Q27690213-2891A110-9643-4E84-B732-D0171D513039Q28267924-90D5EFA8-8181-4C23-A25F-A36059020831Q28303343-8D1EAB3B-E981-4591-8F0E-A952306BC1F7Q28536904-32BAD3BB-B909-40E1-AA20-44FFBDE3394FQ30378479-98566010-0A3D-45B2-9767-AB63C7680E22Q33420841-1EE87B19-BA9F-4F36-952E-EAAC545232B8Q33631088-367B91D0-2B76-48E8-848F-4D2CA9F31D7EQ35037859-E2210AF0-C83A-4578-B2EA-F4CD1BC62EFFQ35090048-F27E33D3-F970-4092-BCE0-3C1A2F0AA1BFQ35462720-6199D1FB-BB7F-4D29-BFFE-29AFC033C384Q35573183-B9DF86B3-009B-46E1-8220-826A9E82C791Q35741515-3F6BF8C2-D2F0-40E1-B614-D497DA3887D3Q36564330-A315384B-3260-460A-8402-152ACBC12C23Q37705854-ECE8F68B-65B3-464A-AB63-95CADAE777E4Q38377610-4E372D70-DE1A-4E61-81DD-DB53FFE1355DQ38950578-C6EB36C3-8017-4638-89BB-5588CD7E0828Q38969903-CCE67500-15C3-4FA5-A314-00A088F2041BQ40029426-90CF4FC7-5115-4B64-B3ED-B28774E0AF78Q40138033-324988C5-CE01-4540-80F7-0752381BC481Q40343332-A47CFB09-0A22-4CDD-A955-AF4093FF1984Q41243043-D52A9A39-0FAF-482E-B150-880516ECF35BQ41511323-73CA0746-BFA4-4E73-AD59-929B333CDA52Q42141370-A827748E-C1C5-4B11-B8DC-460E47EC0DC9Q45013859-CB6D0F5C-B79C-487A-A9FE-4EF14A7F4065Q46815143-A3BA275B-7FE5-4C78-8DDF-A58F0C60DAC9Q47161167-963402E5-4594-4F00-9DB9-FF088AD94DB2Q47317732-BDD09851-660F-42C7-8A2D-E04FC7763DABQ48159506-F21C1CC8-0AB1-42E2-AE1F-C0F47CCB508EQ48539615-00BADE4B-239A-42CC-8783-3F2884D19C52Q48876534-B33FFCE4-D7C1-419E-A6AC-1FDBCE351409Q51810670-78576875-09AC-4361-9235-787CE7091959Q52651324-57DA6D94-4A6F-41D3-9714-DA4B0E733D93Q55421031-32F792BE-946F-4625-982D-65FBD55298C2Q56895697-EA79C4A9-3EBB-4D33-AEDA-5C1E148D1055Q60250460-525D377E-72A9-4B6B-9E1E-494BFDB21E8FQ88446699-58D345B9-5060-4A5C-8765-B29A45CD86E0Q89601782-1B80703F-1B0B-4093-B74A-1A0BE8068713Q89800911-B64A77F4-AC7F-4E60-B623-576313F0895DQ89874776-3349484E-498D-4652-8192-A4090612450A
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Bruno O Villoutreix
@ast
Bruno O Villoutreix
@en
Bruno O Villoutreix
@es
Bruno O Villoutreix
@nl
type
label
Bruno O Villoutreix
@ast
Bruno O Villoutreix
@en
Bruno O Villoutreix
@es
Bruno O Villoutreix
@nl
prefLabel
Bruno O Villoutreix
@ast
Bruno O Villoutreix
@en
Bruno O Villoutreix
@es
Bruno O Villoutreix
@nl
P106
P21
P2456
P31
P496
0000-0002-6456-7730